Results 141 to 150 of about 70,416 (256)

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer

Cancer Science, EarlyView.
The glucocorticoid receptor NR3C1 drives prostate cancer radioresistance by upregulating ACSL4. High ACSL4 levels create a lipid metabolic vulnerability. The clinical agent DHA synergizes with ACSL4 to induce lipid peroxidation and ferroptosis, effectively overcoming radioresistance.
Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang   +7 more
wiley   +1 more source

Sorafenib-induced palmoplantar hyperkeratosis.

, 2008
Sorafenib is an oral multikinase inhibitor used in the treatment of renal cell carcinoma. As with single kinase inhibitors, cutaneous adverse events have been reported with sorafenib, specifically a hand-foot reaction complicated by hyperkeratosis.
Lountzis, Nektarios I, MD, Maroon, Michele S   +1 more
core   +1 more source

PABPC1 in Cancer: From a Translational Housekeeper to a Stress‐Responsive Regulatory Hub

Cancer Science, EarlyView.
PABPC1 shifts from a translational housekeeper to a stress‐responsive oncogenic hub via phase separation, PTMs, and non‐coding RNA crosstalk, selectively driving oncogene translation and therapy resistance in cancer. ABSTRACT PABPC1, long recognized as a constitutive translational housekeeper, has emerged as a stress‐responsive translational ...
Cuiwei Zhang, Ye Zhu, Wenbo Long
wiley   +1 more source

Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study

Hepatology Research, EarlyView.
ABSTRACT Aim To evaluate the frequency, imaging characteristics, associated factors, and clinical significance of biliary abnormalities on imaging in patients receiving lenvatinib (LEN) plus cisplatin hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC).
Hirohito Osanai, Kazuto Kozaka, Takashi Matsubara, Norihide Yoneda, Takahiro Ogi, Kenichiro Okumura, Atsushi Takamatsu, Azusa Kitao, Shintaro Yagi, Taro Yamashita, Satoshi Kobayashi   +10 more
wiley   +1 more source

Cumulative Sorafenib N-Oxide Causes Adverse Effects Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma

, 2020
Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC). However, due to its adverse effects, 20% of patients must discontinue sorafenib within 1 month after first ...
Hoshimi Okawa, Miki Shimada, Yuta Kataoka, Yuko Jin, Kanehiko Hisamichi, Masaki Matsuura, Tooru Shimosegawa, Masaru Mori, Masamitsu Maekawa, Nariyasu Mano, Yasuteru Kondo, Takahiro Maejima, Hiroyuki Suzuki, Ph.D Miki Shimada   +13 more
core  

Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single‐Center Study

Hepatology Research, EarlyView.
Among patients with CP‐A HCC initially within the Japan criteria, some lose oncological eligibility for LT before hepatic decompensation. Further studies are needed to identify baseline factors associated with poor outcomes and to evaluate their relevance to future LT candidacy.
Akihiro Seki, Tomoyoshi Chiba, Shintaro Yagi, Rika Horii, Noboru Takata, Hiroki Nomura, Masaki Miyazawa, Tomoyuki Hayashi, Takeshi Terashima, Shinichi Nakanuma, Mitsuyoshi Okazaki, Satoshi Takada, Tatsuya Yamashita, Masao Honda, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita   +16 more
wiley   +1 more source

Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5-b]Pyridine-Acrylonitrile-Based Derivatives as VEGFR-2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma. [PDF]

Drug Dev Res
Mohamed LW, Saadeldin AA, Farag AB.
europepmc   +1 more source

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

, 2016
Monica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf ...
Nehoff H, Pritchard T, Taurin S, Archibald M, Rosengren RJ, Greish K   +5 more
core